Immune Modulation in Ischemic Stroke Management

Ischaemic stroke triggers a complex cascade of immune events that begins with the rapid activation of resident microglia and astrocytes, followed by infiltration of peripheral leukocytes across a compromised blood–brain barrier. Early innate responses, led by neutrophils and monocytes, can exacerbate tissue damage through release of proteases and reactive oxygen species, while later phases depend on adaptive cells, notably T lymphocytes and regulatory T cells, which can either aggravate inflammation or promote repair. Fine‐tuning this balance through targeted modulation of cytokine networks, cell adhesion molecules and immune checkpoints has emerged as a promising strategy. Approaches under investigation range from monoclonal antibodies that block deleterious cell–cell interactions to cell‐based therapies that harness the anti‐inflammatory capacity of regulatory T cells. Advances in understanding the temporal and spatial dynamics of immune cell phenotypes are guiding the design of interventions that mitigate secondary injury without compromising host defence. Successful translation into clinical practice will require integration of immunological biomarkers, personalised risk stratification and optimisation of therapeutic windows to deliver maximal benefit while avoiding unintended immunosuppression.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Research from all publishers

Recent studies have highlighted the bidirectional dialogue between the central nervous system and peripheral immunity in determining stroke outcome. Investigations published in 2024 have detailed how excessive recruitment of circulating leukocytes into the ischaemic brain amplifies secondary injury, and how modulation of chemokine signalling can attenuate cerebral oedema and haemorrhagic transformation. By targeting specific pathways that govern immune cell trafficking, these studies demonstrate reduced infarct volumes in preclinical models.

In 2023, work on glial–immune crosstalk elucidated the dual roles of microglia and astrocytes in blood–brain barrier integrity. This research showed that glial cell-derived exosomes carry signals that either protect or disrupt endothelial tight junctions, depending on the balance of pro- and anti-inflammatory mediators. Modulating exosomal content through pharmacological agents or genetic manipulation has been proposed to preserve barrier function and limit secondary neuroinflammation.

Analysis of T cell responses from 2021 has underlined the temporal dynamics of adaptive immunity after stroke. This body of work clarifies how different T cell subsets infiltrate via blood–brain barrier and meningeal routes, with effector populations exacerbating neuronal injury early on, while regulatory T cells and type 2 helper cells contribute to tissue repair and angiogenesis in later stages. Selective enhancement of protective T cell phenotypes through cytokine therapy or adoptive transfer emerges as a viable translational avenue.

Immune Modulation in Ischemic Stroke Management publication trend

The graph below shows the total number of articles in immune modulation in ischemic stroke management across all publications each year (not limited to Nature Index journals).

Technical terms

Blood–brain barrier (BBB): A selective endothelial interface that regulates exchange between the circulatory system and the brain, maintaining CNS homeostasis.

Microglia: Resident immune cells of the central nervous system that initiate innate responses and clear debris through phagocytosis.

Regulatory T cells (Tregs): A subset of CD4⁺ T lymphocytes with immunosuppressive functions, essential for limiting excessive inflammatory damage.

Cytokines: Small secreted proteins, such as interleukins and chemokines, that mediate communication between immune cells and influence inflammatory outcomes.

Neuroinflammation: The localised inflammatory reaction within the brain or spinal cord, involving both resident glia and infiltrating peripheral immune cells.

References

1. Targeting brain-peripheral immune responses for secondary brain injury after ischemic and hemorrhagic stroke. Journal of Neuroinflammation (2024).
2. Role of Crosstalk between Glial Cells and Immune Cells in Blood-Brain Barrier Damage and Protection after Acute Ischemic Stroke. Aging and Disease (2023).
3. T Cell Response in Ischemic Stroke: From Mechanisms to Translational Insights. Frontiers in Immunology (2021).